tbuckley/cabot-search huggingface dataset:
P5-17-03: The Association between Breast Cancer Related Lymphedema's Risk Factors and Likelihood of Edema Progression.
Authors: MN Skolny, CL Miller, J O'Toole, B Sadek, M Ancukiewicz, AG Taghain
Journal: Cancer Research (2011)

Abstract Purpose/Objective(s): Breast cancer related lymphedema (BCRL) is one of the most feared long term side effects of treatment. Although emergence of the sentinel lymph node biopsy (SLNB) has decreased the rate of BCRL, it continues to be an issue for this population. The goal of this study is to evaluate the prognostic risk factors for BCRL development and progression based on longitudinal prospective limb volume (LV) measurements and associated surgical, radiation and medical oncology factors. Materials/Methods: Since 2005 newly diagnosed breast cancer (BC) patients were prospectively screen via perometery (Pero-System). For this analysis patients were required to have undergone at least four measurements and have at least 24 months of follow up to allow for adequate time for LE development. Bilateral pre-operative volume measurements of the upper extremity were compared to postoperative measurements and at 4 to 6 month intervals to assess for limb volume changes. At each time point (tx), relative volume change (RVC) of the treated arm was calculated using volume ratios of treated (T) to non-treated (N) side compared to the pre-operative baseline (t1) (RVC=(Ttx/Ntx)/(Tt1/Nt1)-1) as described in Ancukiewicz et al 2010. Our institution utilizes &amp;gt;5% RVC as an indicator of lymphedema. For this analysis, mild lymphedema was classified as a RVC of 5–9.9% and moderate lymphedema was classified as a RVC ≥ 10%. A univariate analysis was performed to identify risk factors and likelihood to LE progression. Results: In a cohort of 415 women, 14.4 %(60) and 6.7% (28) developed mild and moderate BCRL, respectively. Twenty percent (14) and 75 %(21) of patients in the mild and moderate cohorts, respectively, had a persistent edema that was documented at a least 2 consecutive data points. Eighty percent (56) and 25% (7) of patients that had a documented incidence of an elevated RVC had returned below an RVC&amp;lt;5% and their subsequent visits. Based on Kendall's Tau P-value of &amp;lt;0.0001 persistent edemas were associated with axillary lymph node dissection (ALND), number of lymph nodes removed, axillary fields and dose of radiation. Conclusion: Breast cancer related lymphedema is a feared long term side effects and negatively impacts the physical and psychological aspects of an individual's life. A condition that is considered manageable but not curable, it is essential providers identify high risk individuals. Establishing a a lymphedema screening program may identify early lymphedema which could be potentially be treated successfully. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-17-03.
890 HAS PEG-IFN-a INDUCED SEVERE THROMBOCYTOPENIA WORSE PLATELET FUNCTION THEN LIVER CIRRHOSIS OR CYTOSTATIC CHEMOTHERAPY INDUCED THROMBOCYTOPENIA?
Authors: M. Ferlitsch, C. Wiener, O. Gal, S. Pramhas, J. Fischer, T. Scherzer, C. Marose, P. Ferenci, M. Peck-Radosavljevic
Journal: Journal of Hepatology (2012)
Abstract 1580: LL-37-mediates tumor antigen-specific-T cell expansion and tumor regression
Authors: Manisha Singh, Chengwen Liu, Yanyan Lou, Josh Gregorio, Curdin Conrad, Patrick Hwu, Willem W. Overwijk, Michel Gilliet
Journal: Cancer Research (2012)

Abstract We previously showed that the endogenous antimicrobial peptide LL-37, when coupled with self DNA, acts as a TLR-9 agonist and activates plasmacytoid dendritic cells (pDC) leading to type I IFN production. As tumor contains many dying cells releasing self DNA, we investigated whether intra-tumoral injection of LL-37 induces anti-tumor immunity through pDC activation. Mice bearing established subcutaneous B16-OVA melanoma were injected intratumorally with LL-37. LL-37 was found to induce IFN-γ expression in treated tumors. Furthermore, LL-37 induced an activation and expansion of OVA-antigen-specific CD8 T cells in draining lymph nodes as well as the tumor micro environment. This process was associated with delay in tumor growth. These findings suggest that LL-37 could induce anti-tumor immunity and provide a promising strategy for melanoma immunotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1580. doi:1538-7445.AM2012-1580
Pulmonary Hypertrophic Osteoarthropathy (Periostitis)
Authors: Alan B. Skorneck, Leonard B. Ginsburg
Journal: New England Journal of Medicine (1958)

CLUBBING and hypertrophic osteoarthropathy usually reflect disease in the lungs and may present the initial overt signs or symptoms of the primary disorder. The bone changes of hypertrophic osteoarthropathy are always accompanied by the soft-tissue changes of clubbing,1 , 2 but clubbing is usually not accompanied by bone change. Under some concepts of etiology, the osteoarthropathy is regarded as simply an advanced response of tissue to the same stimulus that causes clubbing.3 , 4 This "unified" theory has tended to obscure real differences in clinical significance between the findings of clubbing and hypertrophic osteoarthropathy and to cause a loss of definition of the terms . . .
Abstract LB-74: NECCS- The Voice of Cancer Survivorship
Authors: Sanford Jeames
Journal: Cancer Research (2011)

Abstract The disease of cancer extends its impact far beyond the clutches it holds over those diagnosed with cancer. The latest statistics from the American Cancer Society (ACS) estimate that over 500,000 Americans will be diagnosed with cancer in 2011, and these figures do not take into account the thousands of individuals under the age of 18 who are also diagnosed with cancer. A diagnosis of cancer not only affects patients, but also family members, caregivers, employers_all components of life. The New England Coalition of Cancer Survivorship (NECCS) is an organization dedicated to advocating for the wider audience of those affected by cancer. The mission of NECCS is to educate and provide resources about issues related to cancer and cancer survivorship. Other significant aspects of NECCS's mission are to advocate on behalf of those impacted by cancer, and to empower cancer survivors, family members, friends and caregivers by creating strong communities, providing an information network, and providing access to resources, programs and events. To achieve and reach its main goal of acting as the voice to the concerns of cancer survivorship, NECCS has initiated a variety of programs and activities to inform the public of its resources. NECCS is a collaborative partner with many organizations to better facilitate its effectiveness and outreach. NECCS board members serve on the survivorship workgroup of the Massachusetts Comp Cancer Coalition, the Leukemia/Lymphoma Society of New England and the New England Division of the American Cancer Society. NECCS programs include the Speakers' Bureau and Caregiver Program, which provides NECCS members to various community groups to share their experiences with cancer. NECCS provides printed materials through in the form of tip sheets, which highlight cancer survivors, caregivers and advocates, as well as providing information about the latest research. The NECCS website has links to state, regional and national organizations that address the concerns of cancer survivorship. A recent online campaign resulted in over 100 new members joining NECCS via its Facebook and Twitter accounts. NECCS also participated in the Boston Health Fair and was featured at a recent Boston Red Sox baseball game for its contributions to the Greater Boston area and surrounding communities. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-74. doi:10.1158/1538-7445.AM2011-LB-74
AB1364 Death analysis of 144 rheumatoid arthritis patients over the last 24 years
Authors: M. Hayashi, T. Kojima, N. Ishiguro, Y. Hirano, T. Kobayakawa, T. Kanamono
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Life expectancy for rheumatoid arthritis (RA) patients is 10 years less than that for other adults. However, there have been major pharmacotherapeutic and surgical advances in the treatment of RA patients. In this study, we investigated life expectancy and death trends in RA patients at a single Japanese institute. <h3>Objectives</h3> To investigate trends associated with life expectancy in RA patients by reviewing the records of 144 patients who died over the past 24 years at Nagano Red Cross Hospital. <h3>Methods</h3> Of all 899 RA patients at our institute, the records of 144 patients who died over the past 24 years were reviewed in this study. The records of these patients were divided into two groups: 73 patients who died before the end of 2002 and 71 patients who died after the beginning of 2003. We estimated the gender, age, RA duration, and cause of death by confirming with their relatives via the telephone and not based on the death certificate. <h3>Results</h3> The average ± SD of the 73 patients who died before the end of 2002 and the 71 patients who died after the beginning of 2003 were as follows: male ratio 23.6% vs. 36.6% for those in the former versus latter group; age at death 72.0±10.5 years vs. 77.0±9.01 years; RA duration (from RA onset to death) 15.7±10.9 years vs. 20.7±12.7 years; and death from infection 24.7% vs. 39.4%. The latter group was significantly higher than the former group in these aspects, but no significant difference in the cancer death rate was noted (16.4% vs. 15.5%). The latter included three cases patients with a history of treatment with biological agents, all of whom had been treated with etanercept (ETN) alone. Two of these patients died from pneumonia and one from sepsis. <h3>Conclusions</h3> In July 2003, infliximab, which is now one of 6 biological agents approved for RA treatment in Japan, was approved first for use. Because RA duration and age at death among RA patients were equally prolonged by five years after 2003 than before 2003, life expectancy of RA patients from the onset of RA may have been improved through developments in RA treatment, such as the use of biological agents. However, the first cause of death was infection in both groups and was also the cause of death of the three patients treated with ETN alone. Death caused by cardiovascular events was low throughout both periods, unlike in Europe. <h3>Disclosure of Interest</h3> None Declared
Rapid Functional Assay for Multidrug Resistance in Human Tumor Cell Lines Using the Fluorescent Indicator Fluo-3
Authors: D. M. Wall, X. F. Hu, J. R. Zalcberg, J. D. Parkin
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Rapid Functional Assay for Multidrug Resistance in Human Tumor Cell Lines Using the Fluorescent Indicator Fluo-3 Get access Dominic M. Wall, Dominic M. Wall 1Department of Hematology, Repatriation General hospital HospitalHeidelberg, Victoria, Australia Search for other works by this author on: Oxford Academic PubMed Google Scholar Xiu F. Hu, Xiu F. Hu 2Depatmenet of Medical Oncology, Repatriation General HospitalHidelberg, Victoria, Australia Search for other works by this author on: Oxford Academic PubMed Google Scholar J. R. Zalcberg, J. R. Zalcberg * 2Depatmenet of Medical Oncology, Repatriation General HospitalHidelberg, Victoria, Australia * Correspondence to: John R. Zalcberg, MBBS, PhD, FRACP, Department of Hematology, Repatriation General Hospital, Private Bag No. 1, Heidelberg West, Victoria 3081, Australia. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. D. Parkin J. D. Parkin 1Department of Hematology, Repatriation General hospital HospitalHeidelberg, Victoria, Australia Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 3, 6 February 1991, Pages 206–207, https://doi.org/10.1093/jnci/83.3.206 Published: 06 February 1991 Article history Received: 26 July 1990 Revision received: 31 October 1990 Accepted: 09 November 1990 Published: 06 February 1991
Incidental Detection of Arterial Aneurysms With Tc-99m Human Serum Albumin
Authors: KEIKO AOYAGI, NAOYUKI WATANABE, MASASHI YUKIHIRO, TSUNEO HIRANO, TOMIO INOUE, KEIGO ENDO
Journal: Clinical Nuclear Medicine (1996)

Tc-99m human serum albumin gastrointestinal bleeding imaging was performed on a 66-year-old man with vascular Behcet disease, and small-bowel bleeding was demonstrated at 20 minutes after the administration of Tc-99m human serum albumin. Unexpected aneurysms, vascular complications of Behcet disease, were also detected.
The tracking of government spending and development assistance for the elimination of malaria
Authors: Maxwell Birger, Lavanya Singh, Brittney Zelman, Rima Shretta, Abigail Chapin, Joseph L Dieleman
Journal: The Lancet Global Health (2016)

Background Substantial progress has been made in reducing the incidence and prevalence of malaria. In 2016, 111 countries have eliminated malaria and another 35 countries, are making progress toward elimination of the disease. However, little is known about how much governments and donors spend on the prevention and treatment of malaria. Here, we aimed to estimate development assistance for health and government health expenditure for the prevention and treatment of malaria in 35 malaria-eliminating countries.
Endoscopic Sclerotherapy versus Portacaval Shunt in Patients with Severe Cirrhosis and Variceal Hemorrhage
Authors: John P. Cello, James H. Grendell, Richard A. Crass, Donald D. Trunkey, Edith E. Cobb, David C. Heilbron
Journal: New England Journal of Medicine (1984)

Fifty-two patients with severe cirrhosis (Child Class C) and variceal hemorrhage requiring six or more units of blood were randomly assigned to either sclerotherapy or portacaval shunt. Of 38 pretreatment characteristics, only the frequency of active alcoholism differed significantly between the groups. During the initial hospitalization, the patients in the shunt group required significantly more blood (21.5±3.1 units) than did those in the sclerotherapy group (12.3±1.3 units), although the latter had significantly more rebleeding during hospitalization after the procedure (14 of 28 vs. 5 of 24 patients). There was no difference in short-term survival, with 13 patients in the sclerotherapy group discharged alive, as compared with 10 patients in the shunt group. Patients were followed for a mean of 263 days after the initial discharge (range, 8 to 1117). The sclerotherapy group required significantly more days of hospitalization for rebleeding, but we failed to demonstrate any significant difference in long-term survival between the sclerotherapy and shunt groups. Total health-care costs per patient were significantly higher for the shunt group ($23,957±$3,111) than for the sclerotherapy group ($15,364±$2,220). We conclude that sclerotherapy is less costly than portacaval shunt and as effective for the treatment of esophageal varices associated with severe cirrhosis. (N Engl J Med 1984; 311:1589–94.)
Effect of Interferon Gamma on Tryptophan and Pteridine Metabolism of Human Cells
Authors: E. R. WERNER, G. WERNER-FELMAYER, D. FUCHS, A. HAUSEN, G. REIBNEGGER, H. WACHTER
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Effect of Interferon Gamma on Tryptophan and Pteridine Metabolism of Human Cells Get access ERNST R. WERNER, ERNST R. WERNER Institute for Medical Chemistry and Biochemistry, University of InnsbruckA-6020 Innsbruck, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar GABRIELE WERNER-FELMAYER, GABRIELE WERNER-FELMAYER Institute for Medical Chemistry and Biochemistry, University of InnsbruckA-6020 Innsbruck, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar DIETMAR FUCHS, DIETMAR FUCHS Institute for Medical Chemistry and Biochemistry, University of InnsbruckA-6020 Innsbruck, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar ARNO HAUSEN, ARNO HAUSEN Institute for Medical Chemistry and Biochemistry, University of InnsbruckA-6020 Innsbruck, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar GILBERT REIBNEGGER, GILBERT REIBNEGGER Institute for Medical Chemistry and Biochemistry, University of InnsbruckA-6020 Innsbruck, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar HELMUT WACHTER HELMUT WACHTER Institute for Medical Chemistry and Biochemistry, University of InnsbruckA-6020 Innsbruck, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 12, 17 August 1988, Page 974, https://doi.org/10.1093/jnci/80.12.974 Published: 17 August 1988
Multiple metal stenting using a double-balloon endoscope for malignant biliary obstruction in a patient with hepaticojejunostomy
Authors: Hirofumi Kogure, Atsuo Yamada, Hiroyuki Isayama, Tomotaka Saito, Tsuyoshi Hamada, Takashi Sasaki, Natsuyo Yamamoto, Yousuke Nakai, Kenji Hirano, Minoru Tada, Kazuhiko Koike
Journal: Endoscopy (2014)

Endoscopic management of malignant biliary obstruction following hepaticojejunostomy can be challenging. With the advent of the short double-balloon endoscope (DBE), therapeutic biliary interventions are possible in surgically altered anatomy [1] [2]. Additionally, a novel uncovered metal stent (UMS) has been developed with a 200-cm-long, 6-Fr delivery system (Zilver 635; Cook Medical, Winston-Salem, North Carolina, United States) to enable metal stent placement using a short DBE [3]. We present a successful case of multiple metal stenting using a short DBE and UMS for malignant biliary obstruction after hepaticojejunostomy.
S85 The effects of exposure to IL-9 alone or in combination with IL-13 on the mucociliary differentiation of bronchial epithelial cells from normal and asthmatic children.
Authors: J. C. Parker, S. T. Thavagnanam, G. Skibinski, M. D. Shields, L. G. Heaney
Journal: Thorax (2010)

<h3>Background</h3> IL-9 is a pleiotropic Th2 cytokine that has been implicated in the pathogenesis of asthma. IL-9 has been linked to goblet cell hyperplasia and decreased ciliogenesis in animal models and an epithelial injury model in adults. We tested the effects of IL-9 alone and in combination with IL-13, an important cytokine in allergic asthma, during differentiation of bronchial epithelial cells from both asthmatic and normal children. <h3>Hypothesis</h3> We hypothesised that bronchial epithelial cells from normal children exposed to IL-9 would result in goblet cell hyperplasia and decreased ciliogenesis, with additional augmented response when treated with a combination of IL-9 and IL-13. <h3>Methods</h3> We cultured bronchial epithelial cells from asthmatic and normal children at an air–liquid interface for 28 days. We enumerated the presence of goblet and ciliated cells at the end of the experimental period. <h3>Results</h3> IL-9 stimulation alone did not alter goblet cell numbers in differentiating cultures from normal or asthmatic children. IL-9 stimulated PBECs from normal children had reduced ciliated cell numbers and increased MUC5AC secretion at the apical surface which was not seen in asthmatic cells. Combining IL-9 and IL-13 had no additional synergistic effect. <h3>Conclusions</h3> We conclude that IL-9 alone or in combination with IL-13 did not stimulate goblet cell hyperplasia in bronchial epithelial cells cultures from normal children. We have shown that it is does lower the number of ciliated cells during differentiation of PBECs from normal children however this effect is not seen in cells from asthmatic children.
Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014
Authors: D Musso, T Nhan, E Robin, C Roche, D Bierlaire, K Zisou, A Shan Yan, V M Cao-Lormeau, J Broult
Journal: Eurosurveillance (2014)

Since October 2013, French Polynesia has experienced the largest documented outbreak of Zika virus (ZIKAV) infection. To prevent transmission of ZIKAV by blood transfusion, specific nucleic acid testing of blood donors was implemented. From November 2013 to February 2014: 42 (3%) of 1,505 blood donors, although asymptomatic at the time of blood donation, were found positive for ZIKAV by PCR. Our results serve to alert blood safety authorities about the risk of post-transfusion Zika fever.
68Ga-DOTANOC PET/CT Imaging in Glomus Laryngicum
Authors: Punit Sharma, Varun Singh Dhull, Chandrasekhar Bal, Arun Malhotra, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2013)

Glomus laryngicum (laryngeal paraganglioma) are extremely rare neoplasm of the larynx. We here present the 68Ga-DOTANOC PET/CT images of a 40-year-old male patient with glomus laryngicum. In this report, we have highlighted the potential utility and limitations of 68Ga-DOTANOC PET/CT imaging in patients with glomus laryngicum.
La dépose endoscopique sous anesthésie générale de la vidéo-capsule n'altère pas son efficacité diagnostique chez l'enfant
Authors: J Viala, B Bruneau, J Cardey, C Jung, C Martinez-Vinson, JP Cezard, JP Hugot, M Bellaïche
Journal: Endoscopy (2011)

Introduction: La vidéocapsule endoscopique (VCE) est le moyen non irradiant le moins invasif d'explorer l'intestin grêle chez l'enfant. Chez les moins de 6 ans, la VCE peut être déposée dans le duodénum par endoscopie sous anesthésie générale (AG). Nous avons étudié l'impact de cette AG sur la faisabilité et le l'efficacité diagnostique de la VCE.